Evaluation of quadrivalent HPV 6/11/16/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infection

"Objective: In the quadrivalent (types 6/11/16/18) HPV vaccine (GARDASIL®/SILGARD®) clinical program, 73% of women aged 16-26 were naïve to all vaccine HPV types. In these women, prophylactic administration of the vaccine was highly effective in preventing HPV 6/11/16/18-related cervical diseas...

Descripción completa

Detalles Bibliográficos
Autores Principales: Olsson S.-E., Kjaer S.K., Sigurdsson K., Iversen O.-E., Hernandez-Avila M., Wheeler C.M., Perez G., Brown D.R., Koutsky L.A., Tay E.H., García P., Ault K.A., Garland S.M., Leodolter S., Tang G.W.K., Ferris D.G., Paavonen J., Lehtinen M., Steben M., Bosch F.X., Dillner J., Joura E.A., Majewski S., Muñoz N., Myers E.R., Villa L.L., Taddeo F.J., Roberts C., Tadesse A., Bryan J., Maansson R., Vuocolo S., Hesley T.M., Saah A., Barr E., Haupt R.M.
Formato: Artículo (Article)
Lenguaje:Inglés (English)
Publicado: 2009
Materias:
Hpv
Acceso en línea:https://repository.urosario.edu.co/handle/10336/24233
https://doi.org/10.4161/hv.5.10.9515